EP1225885A4 - A therapeutic mixture of hmg-coa reductase inhibitors - Google Patents

A therapeutic mixture of hmg-coa reductase inhibitors

Info

Publication number
EP1225885A4
EP1225885A4 EP00984562A EP00984562A EP1225885A4 EP 1225885 A4 EP1225885 A4 EP 1225885A4 EP 00984562 A EP00984562 A EP 00984562A EP 00984562 A EP00984562 A EP 00984562A EP 1225885 A4 EP1225885 A4 EP 1225885A4
Authority
EP
European Patent Office
Prior art keywords
hmg
coa reductase
reductase inhibitors
therapeutic mixture
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00984562A
Other languages
German (de)
French (fr)
Other versions
EP1225885A2 (en
Inventor
Wayne H Kaesemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogenix Inc
Original Assignee
Angiogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenix Inc filed Critical Angiogenix Inc
Publication of EP1225885A2 publication Critical patent/EP1225885A2/en
Publication of EP1225885A4 publication Critical patent/EP1225885A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP00984562A 1999-10-19 2000-10-19 A therapeutic mixture of hmg-coa reductase inhibitors Withdrawn EP1225885A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42081699A 1999-10-19 1999-10-19
US420816 1999-10-19
PCT/US2000/041304 WO2001028499A2 (en) 1999-10-19 2000-10-19 A therapeutic mixture of hmg-coa reductase inhibitors

Publications (2)

Publication Number Publication Date
EP1225885A2 EP1225885A2 (en) 2002-07-31
EP1225885A4 true EP1225885A4 (en) 2004-04-21

Family

ID=23667961

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00984562A Withdrawn EP1225885A4 (en) 1999-10-19 2000-10-19 A therapeutic mixture of hmg-coa reductase inhibitors

Country Status (5)

Country Link
EP (1) EP1225885A4 (en)
AU (1) AU2116201A (en)
CA (1) CA2388530A1 (en)
MX (1) MXPA02004021A (en)
WO (1) WO2001028499A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
CA2367002A1 (en) 1999-03-19 2000-09-28 Michael A. Moskowitz Increasing cerebral bioavailability of drugs
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd Combination therapy for endothelial dysfunction, angina and diabetes
CN105246472B (en) * 2013-03-15 2018-10-12 武汉朗来科技发展有限公司 Composition containing ornithine and/or L-aminobutanedioic acid and its application
WO2014139469A1 (en) * 2013-03-15 2014-09-18 Wuhan Qr Science And Technology Development Co. Ornithine- or aspartate-containing compositions and the uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURRENT MEDICAL RESEARCH AND OPINION. 2001, vol. 17, no. 4, 2001, pages 267 - 272, ISSN: 0300-7995 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2001, ATHYROS V G ET AL: "Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.", XP002271257, Database accession no. NLM11922400 *
See also references of WO0128499A3 *

Also Published As

Publication number Publication date
AU2116201A (en) 2001-04-30
CA2388530A1 (en) 2001-04-26
WO2001028499A2 (en) 2001-04-26
EP1225885A2 (en) 2002-07-31
MXPA02004021A (en) 2004-08-23
WO2001028499A3 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
EG24027A (en) Pyrrolotriazine inhibitors of kinases
IL154348A0 (en) Therapeutic combination of a cetp inhibitor and atorvastatin
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
PL373156A1 (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
IL154977A0 (en) Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
AU4166400A (en) Alkenyl and alkynyl compounds as inhibitors of factor xa
HK1080734A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
AU6111000A (en) Inhibitors of viral helcase
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
IL132786A0 (en) Hmg-coa reductase inhibitor preparation process
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
EP1225885A4 (en) A therapeutic mixture of hmg-coa reductase inhibitors
GB9914253D0 (en) Synthesis of substitiuted amidines
AU2252101A (en) New synthesis of SPLA2 inhibitors
GB2371748B (en) HMG-COA reductase inhibitor extended release formulation
AU2050001A (en) Synthesis of indole-containing spla2 inhibitors
IL154927A0 (en) Combination of statins and sorbitol dehydrogenase inhibitors
HUP0105145A3 (en) Process for producing hmg-coa reductase inhibitor
AU2177701A (en) Use of hmg-coa reductase inhibitors for treating seborrhea
HUP0201597A3 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
AU4021700A (en) Methods of use of beta1-integrin inhibitors
PL367885A1 (en) Methyl analogs of simvastatin as novel hmg-coa reductase inhibitors
HUP0105000A3 (en) Process for producing hmg-coa reductase inhibitors
AU1822500A (en) Synthesis of 4-ketocyclopentene and cyclopentadiene compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020517

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ANGIOGENIX, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/40 B

Ipc: 7A 61K 31/19 A

Ipc: 7A 61K 31/35 B

Ipc: 7A 61K 31/22 B

Ipc: 7A 61K 31/198 B

Ipc: 7A 61P 25/28 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040310

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060411